Video: Phase III Clinical Trial of Doxorubicin Alone or in Combination with TH-302

Because the investigational drug TH-302 only becomes active in hypoxic cells, it may have potential as an agent to kill hypoxic cancer cells without causing too much damage to normal cells. Cancer cells that are hypoxic often do not succumb to standard chemotherapy or radiation treatment. Medical oncologist William Tap discusses the multicenter clinical trial he is leading to compare doxorubicin (a standard chemotherapy drug for soft tissue sarcoma) plus TH-302 versus doxorubicin alone in patients with locally advanced soft tissue sarcoma that is inoperable or metastatic.